Want to see SE:XVIVO full AI Analyst Report?
XVIVO Stock Chart & Stats
kr192.70
-kr5.00(-1.20%)
At close: 4:00 PM EST
kr192.70
-kr5.00(-1.20%)
Day’s Range― - ―
52-Week Rangekr160.00 - kr310.40
Previous CloseN/A
Volume6.25K
Average Volume (3M)168.41K
Market Cap
kr8.67B
Enterprise Valuekr7.85B
Total Cash (Recent Filing)kr308.14M
Total Debt (Recent Filing)kr122.68M
Price to Earnings (P/E)121.3
Beta1.25
Next Earnings
Jul 14, 2026EPS Estimate
0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.34
Shares Outstanding31,499,470
10 Day Avg. Volume158,765
30 Day Avg. Volume168,408
Financial Highlights & Ratios
PEG Ratio-2.73
Price to Book (P/B)2.78
Price to Sales (P/S)7.24
P/FCF Ratio-38.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)3.82
Revenue Forecast (FY)kr990.50M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables Growth And Hub ModelStrong EVLP consumable growth and an OPO hub rollout underpin a durable recurring-revenue engine: disposables purchased per procedure scale with installed-use. The hub model accelerates utilization adoption across centers, improving lifetime consumable pull-through and stabilizing revenue per device over time.
Conservative Balance Sheet With Zero DebtZero trailing-twelve-month debt and steadily built equity give the company financial flexibility to fund regulatory submissions, geographic expansion, and hub rollouts without refinancing risk. A conservative capital structure supports multi-quarter investments and cushions execution risk.
Clinical Evidence And Regulatory Access ExpandingFavorable clinical outcomes and new regulatory/reimbursement access in France represent structural market-entry progress. Demonstrated efficacy in trials plus early reimbursement reduce commercialization barriers, support adoption by transplant centers, and accelerate payor acceptance across other markets as regulatory dossiers advance.
Bears Say
Abdominal Segment Margin Compression And Mix RiskA rising mix of lower-margin kidney and sales into lower-priced regions materially reduces segment profitability. Unless pricing, manufacturing scale or regional mix improve, abdominal margin pressure can persist and depress consolidated gross margins and long-term EBITDA sustainability.
Commercial Upside Contingent On Regulatory ApprovalsBroader market access for heart and liver depends on regulatory clearances; delays or restrictive approvals would slow adoption, limit reimbursement discussions, and defer durable consumable revenue growth. Regulatory timing uncertainty elevates execution risk for multi-year commercial ramp plans.
Historic Free Cash Flow Volatility And Cash Conversion RiskAlthough operating cash flow recently turned positive, a history of negative FCF and swings indicates working-capital and investment sensitivities. Continued capital spending for hubs, regulatory trials, and scale-up could repressure cash conversion, limiting reinvestment without using cash reserves.
Xvivo Perfusion AB News
XVIVO FAQ
What was Xvivo Perfusion AB’s price range in the past 12 months?
Xvivo Perfusion AB lowest stock price was kr160.00 and its highest was kr310.40 in the past 12 months.
What is Xvivo Perfusion AB’s market cap?
Xvivo Perfusion AB’s market cap is kr8.67B.
When is Xvivo Perfusion AB’s upcoming earnings report date?
Xvivo Perfusion AB’s upcoming earnings report date is Jul 14, 2026 which is in 3 days.
How were Xvivo Perfusion AB’s earnings last quarter?
Xvivo Perfusion AB released its earnings results on Apr 24, 2026. The company reported kr1.15 earnings per share for the quarter, beating the consensus estimate of kr0.944 by kr0.206.
Is Xvivo Perfusion AB overvalued?
According to Wall Street analysts Xvivo Perfusion AB’s price is currently Overvalued.
Does Xvivo Perfusion AB pay dividends?
Xvivo Perfusion AB does not currently pay dividends.
What is Xvivo Perfusion AB’s EPS estimate?
Xvivo Perfusion AB’s EPS estimate is 0.75.
How many shares outstanding does Xvivo Perfusion AB have?
Xvivo Perfusion AB has 31,499,470 shares outstanding.
What happened to Xvivo Perfusion AB’s price movement after its last earnings report?
Xvivo Perfusion AB reported an EPS of kr1.15 in its last earnings report, beating expectations of kr0.944. Following the earnings report the stock price went down -5.867%.
Which hedge fund is a major shareholder of Xvivo Perfusion AB?
Currently, no hedge funds are holding shares in SE:XVIVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xvivo Perfusion AB
Xvivo Perfusion AB (publ) is a medical technology company that creates and supplies advanced solutions for the preservation and perfusion of organs, tissues, and cells, primarily for use in transplantation. The company's global reach extends across Sweden, the United States, both North and South America, Europe, the Middle East, Africa, and the Asia Pacific region. Its product line includes the XVIVO System (XPS), an integrated, ready-to-use cardiac bypass system designed to facilitate safe normothermic ex vivo lung perfusion (EVLP). To support this, the XPS Disposable Lung Kit offers all the necessary sterile, pre-packed components for EVLP procedures. Xvivo also provides STEEN Solution, an optimally formulated buffered extracellular solution specifically for perfusing isolated donor lungs during EVLP. Additional offerings comprise Perfadex Plus, an extracellular, low-potassium, dextran-based electrolyte preservation solution, and the XVIVO Silicone Tubing Set, used for efficient flushing of donor lungs during the procurement process. The company also manufactures the XVIVO LS and XVIVO Disposable Lung Set, both critical devices for EVLP. Furthermore, Xvivo provides the XVIVO Organ Chamber, a sterile, single-use disposable container for temporarily housing isolated lungs before transplantation, and the XVIVO Lung Cannula Set, another sterile, single-use disposable medical product. Established in 1998, Xvivo Perfusion AB (publ) is headquartered in Gothenburg, Sweden.
XVIVO Company Deck
XVIVO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong operational momentum: record sales, double-digit organic growth across thoracic and abdominal, robust EVLP consumable growth (+56%), a compelling clinical evidence package for the Heart Assist (reduced severe PGD and improved 1-year survival), rapid Flowhawk adoption (+62%), and positive cash flow for the second consecutive quarter. Headwinds were primarily margin pressure in abdominal and services (organ recovery), dependency on regulatory approvals for broader heart and liver commercialization, one-time go-to-market costs (SEK 7m), and some revenue concentration risk in EVLP. Overall the positive commercial and clinical developments and improving cash generation outweigh the manageable operational and regulatory risks.View all SE:XVIVO earnings summariesTechnical Analysis
1 Day
3 Days
1 Week
1 Month
Options Prices
Currently, No data available
---










